LCL-161 | Phase | Patient | Refrac | Combined | Dis. | Outcomes | Adv. Effects | ORR | Stabil. | Bio.M | URL/Ref |
---|---|---|---|---|---|---|---|---|---|---|---|
NCT01240655 | Ib | Pre-treated | Yes | PAC | AST | MTD | Neut/GI | 27.6% PR; 25% PD | 36.8% | – | |
NCT01968915 | I/II | – | – | -single−/ PAC | AST | – | Neut/Diar | DISC. | – | – | |
NCT01098838 | I/II | Pre-treated | – | -single- | AST | MTD | Naus/Vom/ Anem | 0% ORR | 19% | cIAP | [418] |